Celldex Proposes Public Stock Offering to Fund Barzolvolimab Commercialization
CLDX has more than doubled off its 52-week low of $14.4.
Summary
Celldex Therapeutics announced a proposed underwritten public offering of common stock, including an option for underwriters to purchase additional shares. The company intends to use the net proceeds to fund ongoing commercial readiness activities and the potential commercial launch of barzolvolimab, if approved, for chronic spontaneous urticaria (CSU), as well as for further clinical development and general corporate purposes. This financing move follows highly positive Phase 2 data for barzolvolimab reported just days ago. While strategically aimed at funding the commercialization of a promising drug, the offering is inherently dilutive for existing shareholders and is likely to exert near-term downward pressure on the stock. Traders will closely watch the final terms and size of the offering for its full impact.
At the time of this announcement, CLDX was trading at $30.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $14.40 to $34.52. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.